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Letter to the Editor
To the Editor—In the 15 August 2010
issue of Clinical Infectious Diseases,
Fitzwater et al report on serial acid fast
bacilli smear and culture conversion
rates over 26 weeks in a cohort of 93
sputum culture–positive tuberculosis
(TB) patients started on standardized
ﬁrst-line treatment in a Lima, Peru, di-
rectly observed therapy short-course
(DOTS) program [1]. The authors note
that median conversion times for smears
and cultures, respectively, were 17.5 days
and 38.5 days, and that at 60 days (a
time point at which treatment failure is
commonly suspected in individuals re-
maining smear or culture positive),
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sistant (MDR) and 10% of non-MDR
patients remained culture positive. Al-
though Fitzwater et al question the view
‘‘that patients with TB who are culture
positive at baseline are noninfectious
after 2 weeks of treatment or a negative
smear’’ [1] and claim persistent culture
positivity for months as a reason to be-
lieve many patients remained infectious,
we do not believe their data justify these
conclusions.
Epidemiologic studies have conﬁrmed
the disassociation between smear and
culture positivity and infectiousness in
effectively treated patients. In Madras,
India, the risk of infection or disease
among household contacts of TB pa-
tients was no different between contacts
of patients treated in the hospital and
contacts of those returning home to
complete treatment [2]. Moreover,
Gunnels and colleagues demonstrated
no difference in conversion rates among
household contacts of effectively treated
patients regardless of sputum-smear
status [3]. However, the most direct
evidence of the impact of treatment on
reducing patient infectiousness comes
from several experiments wherein large
numbers of guinea pigs (an animal model
well established to quantify TB trans-
mission) breathed the air exhausted from
experimental TB wards. In Riley’s study
60 years ago, all transmission to guinea
pigs was interrupted when sputum
smear–positive patients were admitted to
the ward on the same day they started
effective therapy for drug-susceptible TB,
and resumed when drug-resistant pa-
tients on ineffective treatment were ad-
mitted [4]. In a second, similar study,
Riley and colleagues directly compared
the infectiousness of treated and un-
treated patients and demonstrated the
extremely rapid effect of treatment on
reducing transmission. Compared with
untreated sputum smear–positive pa-
tients with drug susceptible TB, those
started on treatment the same day as
admission were only 2% as infectious
[5]. Recently, Escombe et al found
similar results by exposing guinea pigs
to air from an experimental ward of
TB/HIV co-infected patients in Lima,
Peru. They found 97% of guinea pig
infections were attributable to just 8
unsuspected or inadequately treated
MDR-TB patients [6]. Transmission of
TB to 3 guinea pigs occurred from just
3 patients with drug-susceptible TB
who experienced delays in starting ef-
fective treatment or who were off
therapy because of side effects [6].
Unfortunately, the study by Fitzwater
et al does not assess infectiousness per se.
Smear or culture positivity does not
necessarily equate with prolonged in-
fectiousness. To demonstrate prolonged
infectiousness, one would need to exam-
ine transmission from these patients. One
could evaluate household contact con-
version or disease rates after initiation
of source-case treatment, for example.
Alternatively, in the context of a well-
functioning DOTS program like the one
described in the paper, one could com-
pare TB-skin test conversion or disease
rates among household contacts strat-
iﬁed by effective versus ineffective (eg,
receiving a ﬁrst-line regimen for MDR-
TB) treatment for the source case’s TB.
As we point out, critically relevant to
any discussion on infectiousness is
whether patients receive effective ther-
apy for TB. In Fitzwater et al’s study, the
authors note that only 4 of 9 MDR-TB
patients received tailored regimens based
on in vitro drug-susceptibility testing
results, and that only 2 of these 4 re-
ceived such regimens more than 2 weeks
before study completion. If any of the
patients in this study were likely to have
been infectious for a prolonged time, it
would be the 7 MDR-TB patients who
did not receive timely tailored therapy
but instead received a ﬁrst-line regimen
of rifampicin, isoniazid, ethambutol,
and pyrazinamide.
Whereas the use of 2-month time
points of smear and culture conversion
may be appropriate for gauging an
individual patient’s response to or the
failure of a given treatment regimen, it
may not be appropriate for assuming an
individual’s ongoing infectiousness. In-
fectiousness is related not just to
the presence of viable Mycobacterium
tuberculosis on sputum smear or in cul-
ture but also to the ability of patients to
generate transmissible aerosols of
M. tuberculosis and the ability of trans-
mitted organisms to cause disease. Each
of these factors may be signiﬁcantly
mitigated when one considers the com-
plex, yet poorly deﬁned, interactions
between microbe, host, and drugs that
are bound to occur within the lungs and
airways of TB patients and within mi-
croscopic droplets after aerosolization.
Although we contend that the
evidence from Fitzwater et al’s study is
insufﬁcient to conclude prolonged in-
fectiousness of patients, we applaud the
emphasis the authors place on the need
to expand rapid culture methods, im-
plement timely DST, and start early
MDR-speciﬁc treatment regimens in
patients needing them. Scaling up these
processes is critical to getting TB pa-
tients on effective drug regimens with
their demonstrable rapid and profound
effect on infectiousness.
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